Abstract
Bivalirudin, a DTI, has evolved from relative obscurity as an anticoagulation option in patients resistant to or allergic to either LMWH or UFH to a commonly used, safe alternative. Most of the early studies comparing bivalirudin to UFH with or without a GP IIb/IIIa agent had composite endpoints (death, MI, bleeding) whose statistical significance were driven exclusively by a significant reduction in bleeding. Newer studies now demonstrate reductions in mortality, which has led to a paradigm shift in anticoagulant choice both in elective and emergent coronary procedures. We present the major studies that have brought bivalirudin to the forefront of coronary artery disease, specifically coronary interventional procedures.
Keywords: Direct thrombin inhibitors, bivalirudin, heparin, coronary artery disease, percutaneous coronary intervention.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Bivalirudin in Patients with Coronary Artery Disease
Volume: 8 Issue: 4
Author(s): Julie A. Linden and George S. Chrysant
Affiliation:
Keywords: Direct thrombin inhibitors, bivalirudin, heparin, coronary artery disease, percutaneous coronary intervention.
Abstract: Bivalirudin, a DTI, has evolved from relative obscurity as an anticoagulation option in patients resistant to or allergic to either LMWH or UFH to a commonly used, safe alternative. Most of the early studies comparing bivalirudin to UFH with or without a GP IIb/IIIa agent had composite endpoints (death, MI, bleeding) whose statistical significance were driven exclusively by a significant reduction in bleeding. Newer studies now demonstrate reductions in mortality, which has led to a paradigm shift in anticoagulant choice both in elective and emergent coronary procedures. We present the major studies that have brought bivalirudin to the forefront of coronary artery disease, specifically coronary interventional procedures.
Export Options
About this article
Cite this article as:
A. Linden Julie and S. Chrysant George, Bivalirudin in Patients with Coronary Artery Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2010; 8 (4) . https://dx.doi.org/10.2174/187152510792481225
DOI https://dx.doi.org/10.2174/187152510792481225 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Retrometabolic Syntheses of Astaxanthin (3,3-dihydroxy-β,β-carotene-4,4-dione) Conjugates: A Novel Approach to Oral and Parenteral Cardioprotection
Cardiovascular & Hematological Agents in Medicinal Chemistry Renin Activity and Aldosterone Assay Among Nigerians with Hypertension and Normotension: An Insight into Normative Values and Clinical Correlates
Current Hypertension Reviews An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan Protects Against Neurological Deficits and Prolongs Survival in Spontaneously Hypertensive Rats Stroke-Prone (SHR-SP) Infused with Ang II
Vascular Disease Prevention (Discontinued) Multimodalities Imaging of Immunoglobulin 4-related Cardiovascular Disorders
Current Cardiology Reviews On-Pump Coronary Artery Bypass Graft: The State of the Art
Reviews on Recent Clinical Trials Cervicocranial Arterial Dissection: An Analysis of the Clinical Features, Prognosis, and Treatment Efficacy
Current Neurovascular Research Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development
Current Medicinal Chemistry Neuroprotective Effects of Lithium in Human Brain? Food for Thought
Current Alzheimer Research NOAC or warfarin for Atrial Fibrillation: does time in therapeutic range matter?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Phytochemical, Pharmacological Activities and Ayurvedic Significances of Magical Plant <i>Mimosa pudica Linn</i>
Mini-Reviews in Organic Chemistry Novel Oral Anticoagulants in the Management of Polycythemia Vera and Essential Thrombocythemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Long Non-coding RNAs: Pivotal Epigenetic Regulators in Diabetic Retinopathy
Current Genomics Cell Sheet Technology for Heart Failure
Current Pharmaceutical Biotechnology Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
Current Vascular Pharmacology From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Current Vascular Pharmacology Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam
Pharmaceutical Nanotechnology Role of Chymase in Preeclampsia
Current Vascular Pharmacology Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
Current Neuropharmacology